Journal of the Endocrine Society · 2025
Semen Cryopreservation and Semen Quality in Transfeminine Adolescents Prior to Hormone Therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aslam Mohsin, Norup Pernille Badsberg, Haahr Mette Ewers, Pagsberg Anne Katrine, Giraldi Annamaria, Jørgensen Niels, Main Katharina Maria
Аннотация
BACKGROUND: Some transgender individuals wish to become biological parents in the future and transfeminine persons may be offered cryopreservation of semen before starting hormone therapy. However, there is a lack of knowledge about semen cryopreservation outcomes among transfeminine adolescents seeking gender-affirming care.
OBJECTIVE: To investigate transfeminine adolescents who decide for or against semen cryopreservation.
METHODS: This is a retrospective observational national cohort study of 58 transfeminine individuals aged <18 years, assessing clinical data, semen parameters, and reproductive hormone levels.
RESULTS: Among the 58 individuals, 23 (39.7%) opted for semen cryopreservation and successfully collected a semen sample. They were older and more advanced in pubertal development compared with those who did not: median age was 16.4 years (range, 13.7-19.4) vs 15.8 years (11.7-17.9); Tanner stage G5 (4-5) vs G3 (2-4); and testis volume 20 mL (15-25) vs 8 mL (3-20). Among 17 individuals with no prior hormone therapy, the median sperm concentration was 11.1 × 106/mL (0.02-163), semen volume 1.8 mL (0.2-3.9), total sperm count 17.8 × 106 (0.1-214.2), and percentage of progressively motile spermatozoa 46% (8-74). Reproductive hormones were within normal ranges for age and registered sex at birth.
CONCLUSION: The percentage of adolescents opting for semen cryopreservation was comparable to other countries with a publicly financed national healthcare system. Overall, semen quality was impaired.
OBJECTIVE: To investigate transfeminine adolescents who decide for or against semen cryopreservation.
METHODS: This is a retrospective observational national cohort study of 58 transfeminine individuals aged <18 years, assessing clinical data, semen parameters, and reproductive hormone levels.
RESULTS: Among the 58 individuals, 23 (39.7%) opted for semen cryopreservation and successfully collected a semen sample. They were older and more advanced in pubertal development compared with those who did not: median age was 16.4 years (range, 13.7-19.4) vs 15.8 years (11.7-17.9); Tanner stage G5 (4-5) vs G3 (2-4); and testis volume 20 mL (15-25) vs 8 mL (3-20). Among 17 individuals with no prior hormone therapy, the median sperm concentration was 11.1 × 106/mL (0.02-163), semen volume 1.8 mL (0.2-3.9), total sperm count 17.8 × 106 (0.1-214.2), and percentage of progressively motile spermatozoa 46% (8-74). Reproductive hormones were within normal ranges for age and registered sex at birth.
CONCLUSION: The percentage of adolescents opting for semen cryopreservation was comparable to other countries with a publicly financed national healthcare system. Overall, semen quality was impaired.